$22.17
0.95% today
Nasdaq, Sep 22, 06:48 pm CET
ISIN
US9183851057
Symbol
VTVT

vTv Therapeutics, Inc. Class A Stock price

$22.38
+6.86 44.21% 1M
+4.12 22.56% 6M
+8.57 62.07% YTD
+7.45 49.90% 1Y
-18.82 45.68% 3Y
-60.02 72.84% 5Y
-266.82 92.26% 10Y
-413.22 94.86% 20Y
Nasdaq, Closing price Fri, Sep 19 2025
+1.03 4.83%
ISIN
US9183851057
Symbol
VTVT
Industry

Key metrics

Basic
Market capitalization
$71.5m
Enterprise Value
$45.6m
Net debt
positive
Cash
$25.9m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3,574.7 | -
EV/Sales
2,278.7 | -
EV/FCF
negative
P/B
25.9
Financial Health
Equity Ratio
31.9%
Return on Equity
-151.3%
ROCE
-121.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$20.0k | $0.0
EBITDA
$-25.6m | -
EBIT
$-25.6m | $-30.8m
Net Income
$-19.6m | $-11.9m
Free Cash Flow
$-22.0m
Growth (TTM | estimate)
Revenue
-98.0% | -100.0%
EBITDA
5.2% | -
EBIT
5.3% | -27.2%
Net Income
3.0% | 35.8%
Free Cash Flow
-1.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-150,388.2% | -
EBIT
-150,717.7%
Net
-115,029.4% | -
Free Cash Flow
-129,558.8%
More
EPS
$-3.0
FCF per Share
$-6.9
Short interest
1.3%
Employees
23
Rev per Employee
$40.0k
Show more

Is vTv Therapeutics, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

vTv Therapeutics, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:

Buy
88%
Hold
13%

Financial data from vTv Therapeutics, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.02 0.02
98% 98%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
4% 4%
66,250%
- Research and Development Expense 12 12
12% 12%
61,950%
-26 -26
5% 5%
-127,850%
- Depreciation and Amortization 0.06 0.06
33% 33%
300%
EBIT (Operating Income) EBIT -26 -26
5% 5%
-128,110%
Net Profit -20 -20
3% 3%
-97,800%

In millions USD.

Don't miss a Thing! We will send you all news about vTv Therapeutics, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

vTv Therapeutics, Inc. Class A Stock News

Neutral
GlobeNewsWire
7 days ago
HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the European Association for the Study of Diabetes (EASD) 61st Annual Meeting.
Neutral
GlobeNewsWire
19 days ago
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor confe...
Neutral
GlobeNewsWire
19 days ago
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor confe...
More vTv Therapeutics, Inc. Class A News

Company Profile

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Head office United States
CEO Paul Sekhri
Employees 23
Founded 2015
Website vtvtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today